Capital Fund Management S.A. trimmed its holdings in Horizon Pharma PLC (NASDAQ:HZNP) by 14.2% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 701,855 shares of the biopharmaceutical company’s stock after selling 116,160 shares during the quarter. Capital Fund Management S.A. owned about 0.43% of Horizon Pharma PLC worth $8,331,000 at the end of the most recent quarter.
Several other institutional investors have also added to or reduced their stakes in the stock. Profund Advisors LLC increased its position in Horizon Pharma PLC by 0.8% in the first quarter. Profund Advisors LLC now owns 13,508 shares of the biopharmaceutical company’s stock worth $200,000 after purchasing an additional 112 shares during the period. US Bancorp DE increased its position in Horizon Pharma PLC by 1.2% in the first quarter. US Bancorp DE now owns 32,050 shares of the biopharmaceutical company’s stock worth $473,000 after purchasing an additional 368 shares during the period. Prudential Financial Inc. increased its position in Horizon Pharma PLC by 2.6% in the first quarter. Prudential Financial Inc. now owns 16,680 shares of the biopharmaceutical company’s stock worth $247,000 after purchasing an additional 420 shares during the period. Sheaff Brock Investment Advisors LLC increased its position in Horizon Pharma PLC by 5.0% in the second quarter. Sheaff Brock Investment Advisors LLC now owns 10,500 shares of the biopharmaceutical company’s stock worth $125,000 after purchasing an additional 500 shares during the period. Finally, Bank of Montreal Can increased its position in Horizon Pharma PLC by 16.3% in the second quarter. Bank of Montreal Can now owns 9,809 shares of the biopharmaceutical company’s stock worth $116,000 after purchasing an additional 1,378 shares during the period. 82.30% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Horizon Pharma PLC (NASDAQ:HZNP) Shares Sold by Capital Fund Management S.A.” was originally published by TrueBlueTribune and is the property of of TrueBlueTribune. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.truebluetribune.com/2017/09/17/horizon-pharma-plc-hznp-shares-sold-by-capital-fund-management-s-a.html.
Several research firms have recently issued reports on HZNP. UBS AG set a $16.00 price objective on Horizon Pharma PLC and gave the company a “buy” rating in a research report on Wednesday, June 7th. Mizuho restated a “neutral” rating and issued a $9.00 target price (down previously from $10.00) on shares of Horizon Pharma PLC in a research note on Wednesday, August 9th. BMO Capital Markets restated an “outperform” rating and issued a $18.00 target price (up previously from $17.00) on shares of Horizon Pharma PLC in a research note on Thursday, August 10th. Zacks Investment Research upgraded Horizon Pharma PLC from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. Finally, Piper Jaffray Companies set a $18.00 target price on Horizon Pharma PLC and gave the company a “buy” rating in a research note on Sunday, September 10th. Five analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $18.67.
Shares of Horizon Pharma PLC (HZNP) traded down 1.46% during mid-day trading on Friday, hitting $12.11. The company had a trading volume of 7,899,141 shares. The company’s 50-day moving average is $12.81 and its 200 day moving average is $13.04. Horizon Pharma PLC has a one year low of $9.45 and a one year high of $21.98. The company’s market capitalization is $1.98 billion.
Horizon Pharma PLC (NASDAQ:HZNP) last issued its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported $0.41 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.29. The company had revenue of $289.51 million during the quarter, compared to the consensus estimate of $237.01 million. Horizon Pharma PLC had a negative net margin of 42.40% and a positive return on equity of 22.85%. Horizon Pharma PLC’s revenue for the quarter was up 12.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.56 earnings per share. On average, equities research analysts forecast that Horizon Pharma PLC will post $1.08 EPS for the current fiscal year.
Horizon Pharma PLC Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.